Chemours (NYSE:CC) Upgraded to “Hold” at Zacks Research

Zacks Research upgraded shares of Chemours (NYSE:CC) from a strong sell rating to a hold rating in a report published on Thursday,Zacks reports.

Other equities analysts have also issued research reports about the company. Royal Bank Of Canada reduced their price objective on Chemours from $26.00 to $22.00 and set an “outperform” rating for the company in a research note on Thursday, August 6th. BMO Capital Markets lowered their target price on Chemours from $26.00 to $18.00 and set an “outperform” rating on the stock in a research note on Thursday, August 13th. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $17.00 target price on shares of Chemours in a report on Thursday, August 13th. Morgan Stanley set a $18.00 price target on Chemours in a research report on Monday, August 10th. Finally, Alembic Global Advisors reissued an “overweight” rating and issued a $30.00 price target on shares of Chemours in a report on Wednesday, May 13th. Five research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $20.10.

Chemours Stock Performance

Shares of NYSE CC opened at $15.04 on Thursday. The company has a 50 day simple moving average of $16.39 and a two-hundred day simple moving average of $19.64. The stock has a market cap of $2.26 billion, a price-to-earnings ratio of -7.88 and a beta of 1.42. The company has a current ratio of 1.66, a quick ratio of 0.88 and a debt-to-equity ratio of 18.98. Chemours has a 12 month low of $10.44 and a 12 month high of $28.67.

Chemours (NYSE:CC) last issued its earnings results on Tuesday, August 4th. The specialty chemicals company reported $0.42 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.49 by ($0.07). Chemours had a positive return on equity of 60.64% and a negative net margin of 5.00%.The business had revenue of $1.59 billion for the quarter, compared to analysts’ expectations of $1.65 billion. During the same period last year, the business earned ($2.54) EPS. The company’s revenue for the quarter was down 1.5% on a year-over-year basis. As a group, analysts predict that Chemours will post 0.87 earnings per share for the current year.

Chemours Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 15th. Stockholders of record on Friday, August 14th will be paid a dividend of $0.0875 per share. This represents a $0.35 annualized dividend and a dividend yield of 2.3%. The ex-dividend date of this dividend is Friday, August 14th. Chemours’s dividend payout ratio is presently -18.32%.

Insider Transactions at Chemours

In other Chemours news, CEO Denise Dignam purchased 3,378 shares of Chemours stock in a transaction that occurred on Tuesday, August 11th. The stock was bought at an average price of $14.95 per share, with a total value of $50,501.10. Following the acquisition, the chief executive officer owned 339,916 shares of the company’s stock, valued at $5,081,744.20. This trade represents a 1.00% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Shane Hostetter purchased 3,350 shares of Chemours stock in a transaction that occurred on Thursday, August 6th. The stock was acquired at an average cost of $14.94 per share, with a total value of $50,049.00. Following the acquisition, the chief financial officer directly owned 102,698 shares in the company, valued at $1,534,308.12. This trade represents a 3.37% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have bought a total of 8,663 shares of company stock valued at $130,601 in the last ninety days. 0.85% of the stock is currently owned by corporate insiders.

Institutional Trading of Chemours

A number of institutional investors and hedge funds have recently made changes to their positions in the business. BlackRock Inc. purchased a new position in shares of Chemours during the 2nd quarter valued at approximately $477,769,000. State Street Corp increased its holdings in Chemours by 22.7% in the 2nd quarter. State Street Corp now owns 6,114,328 shares of the specialty chemicals company’s stock worth $70,009,000 after acquiring an additional 1,131,682 shares in the last quarter. Ameriprise Financial Inc. raised its position in Chemours by 13.8% during the third quarter. Ameriprise Financial Inc. now owns 4,796,153 shares of the specialty chemicals company’s stock worth $75,971,000 after acquiring an additional 580,089 shares during the period. UBS Group AG raised its position in Chemours by 0.3% during the third quarter. UBS Group AG now owns 4,754,492 shares of the specialty chemicals company’s stock worth $75,311,000 after acquiring an additional 14,865 shares during the period. Finally, Cooper Creek Partners Management LLC purchased a new position in Chemours during the third quarter valued at $63,103,000. 76.26% of the stock is currently owned by hedge funds and other institutional investors.

More Chemours News

Here are the key news stories impacting Chemours this week:

• Positive Sentiment: Chemours, DuPont and Corteva agreed to pay $455 million over 15 years to resolve claims brought by North Carolina and 11 local entities involving PFAS and other historical discharges from Chemours’ Fayetteville Works plant, as well as certain AFFF-related claims. Chemours’ share is approximately $180 million on a net-present-value basis, and the company said the obligation is covered by existing accruals, limiting the immediate earnings impact. Chemours, DuPont and Corteva Reach Agreement to Resolve PFAS-Related Claims in North Carolina
• Positive Sentiment: The settlement removes a significant portion of litigation uncertainty tied to the Fayetteville Works site and clarifies future cash obligations, which investors viewed favorably. Reports indicated Chemours shares rose during the session following the announcement. Why Is Chemours Stock Trading Higher Today?
• Neutral Sentiment: Several reports describe the agreement as a $380 million settlement with 11 public entities, while other headlines cite $590 million. These figures appear to reflect different components or descriptions of the broader resolution; the companies’ announced terms identify total settlement payments of $455 million over 15 years. Chemours, DuPont, Corteva settle North Carolina forever chemicals claims for $455 million
• Negative Sentiment: The agreement still represents a substantial long-term liability and does not eliminate broader PFAS-related regulatory, cleanup or litigation risks. Chemours’ results already show pressure from weaker revenue and an earnings miss, making continued legal-cost management important for investors.

About Chemours

The Chemours Company (NYSE: CC) is a global chemistry company headquartered in Wilmington, Delaware. Formed in 2015 through a spin-off from DuPont, Chemours develops and manufactures chemical products used in industries including transportation, electronics, energy, construction, and consumer goods.

The company operates through businesses focused on thermal and specialized solutions, titanium technologies, and advanced performance materials. Its products include refrigerants and heat-transfer fluids, titanium dioxide pigments used to provide whiteness and opacity in coatings, plastics, and paper, as well as fluoropolymers, specialty fluids, and other performance materials used in demanding industrial applications.

Chemours serves customers in North America, Latin America, Europe, the Asia-Pacific region, and other international markets through manufacturing facilities, research and development operations, and commercial activities around the world.